Skip to lesson
OncoGuideeducationDiana’s wiki
THE EDUCATION LIBRARY

Ki-67 proliferation index

In one sentence

Ki-67 is a protein associated with the active cell cycle; its proliferation index is the percentage of evaluated tumor-cell nuclei that stain positive under a specified method.

The intuition

Think of Ki-67 as a snapshot of cells engaged in the cell cycle. The cell cycle includes preparing to divide, copying genetic material and division itself. A snapshot can describe the fraction of cells carrying a marker at that moment; it cannot tell you how fast the whole tumor will double in size.

It helps to say the denominator aloud: “positive tumor-cell nuclei out of the tumor-cell nuclei evaluated.” That makes the number more concrete than simply calling it a “growth score.”

How it works

Ki-67 is a nuclear protein associated with active cell-cycle phases. It is generally absent from resting cells in G0, the quiescent state outside the active cycle. Because several phases precede visible division, Ki-67 staining is not the same as counting mitotic figures. The International Ki67 in Breast Cancer Working Group explains this biology and the limits of its clinical use.

The usual tissue test is immunohistochemistry (IHC), an antibody stain. A pathologist identifies the relevant tumor-cell nuclei, assesses which stain positive, and reports their proportion as a percentage. MIB-1 is a commonly used antibody for the test, not a separate biological growth process.

Tissue section and Ki-67 stain Identify relevant tumor-cell nuclei Count positive nuclei and evaluated nuclei Positive divided by evaluated, multiplied by 100 Ki-67 percentage with method and specimen context Interpret for the specific clinical or research question

The fraction depends on where and how cells are evaluated. A hotspot is an area with particularly high staining. A broader scoring method samples regions across the tumor. These methods can give different numbers without an arithmetic mistake. Tissue preservation, staining and scorer calibration also matter.

Why it matters in cancer

Ki-67 adds information about proliferation-related activity. It can be studied as a prognostic marker or as a change after treatment under a defined protocol. It does not by itself demonstrate that a drug killed cells or improved outcomes.

Clinical interpretation is population-specific. The working group's validated-use discussion concerns selected, anatomically favorable ER-positive, HER2-negative early breast cancers under standardized scoring. Estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) are separate clinical receptor measurements. Those conclusions are not a universal treatment-selection rule for TNBC. The current CAP protocol treats Ki-67 as an optional reporting element, not a replacement for the core receptor profile.

Worked example

In a deliberately simplified fictional field, 30 of 100 evaluated tumor-cell nuclei stain positive. The Ki-67 index for that field is 30%. It does not mean that 30% of the cells are visibly dividing right now, that the tumor grows by 30% per day, or that recurrence risk is 30%.

Now imagine the sample also has a quieter region. A hotspot-only count and a broader count could differ. Before interpreting that difference as a biological change, compare the specimen, sampling and scoring method. A real report requires the laboratory's validated approach; this small count is only an arithmetic teaching example.

Common confusions

  • Ki-67 is not tumor stage or the complete histologic grade.
  • A proliferation fraction is not a tumor doubling time or a measured rate of cell killing.
  • “High” depends on the method and intended use; there is no single threshold that answers every breast-cancer question.
  • RNA (ribonucleic acid) expression of proliferation genes and a Ki-67 IHC percentage are different measurements.
  • A decrease after treatment can be informative in a study without proving long-term clinical benefit.

How it is measured

Preserve the specimen and time point, antibody and scoring approach, sampled regions, relevant denominator and reported percentage or range. A pre-treatment biopsy and a treated surgical specimen need their own context. Comparing two bare percentages can hide changes in sampling or technique.

Explain it back

What does 30% mean in the fictional field? Thirty out of the hundred evaluated tumor-cell nuclei stained for Ki-67 under that method. Everything beyond that fraction needs additional evidence.

Sources and scope

General education; fictional arithmetic example. Source-checked October 9, 2026. Expert and learner review remain pending. This page does not supply a clinical decision threshold.

Used in